샘플 요청 목록

 카트 문의
시장보고서
상품코드
1782968

세계의 오메가 3 처방약 시장

Omega 3 Prescription Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 378 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

오메가 3 처방약 세계 시장은 2030년까지 16억 달러에 달할 전망

2024년에 13억 달러로 추정되는 오메가 3 처방약 세계 시장은 2030년에는 16억 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 3.0%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 바세파 의약품은 CAGR 2.4%를 기록하며 분석 기간 종료시에는 8억 2,120만 달러에 달할 것으로 예측됩니다. 로바자 의약품 부문은 분석 기간 동안에 CAGR 3.4%의 성장이 전망됩니다.

미국 시장은 3억 5,680만 달러로 추정, 중국은 CAGR 5.5%로 성장 예측

미국의 오메가 3 처방약 시장은 2024년에 3억 5,680만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 5.5%로 2030년까지 3억 290만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.2%와 2.2%로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%로 성장할 것으로 예측됩니다.

오메가 3 처방약 세계 시장 - 주요 동향과 촉진요인 정리

오메가 3 처방약이 심혈관 및 대사 요법에서 임상적 지위를 획득한 이유는 무엇일까?

오메가 3 처방약은 특히 고중성지방혈증, 심혈관질환(CVD) 및 기타 염증으로 인한 만성질환을 관리하기 위해 제약 업계에서 중요한 구성요소로 부상하고 있습니다. 건강보조식품과 달리, 이러한 의약품은 정제, 농축, 효능 및 안전성에 대한 임상시험을 거쳤으며, 의료 개입에 적합한 고용량의 에이코사펜타엔산(EPA) 및/또는 도코사헥사엔산(DHA)을 제공합니다. 중성지방 수치를 낮추고, 지질 프로필을 개선하며, 잔여 심혈관 위험을 감소시키는 역할은 REDUCE-IT와 같은 대규모 임상시험을 통해 입증되었으며, 고용량 이코사펜토에틸(EPA)이 심혈관계 결과에 유익하다는 것을 입증했습니다. 이러한 연구 결과는 오메가 3를 기반으로 한 치료제가 다양한 치료 가이드라인에 포함되고, 순환기 전문의와 일차 의료 서비스 제공자들이 오메가 3를 처방하는 데 박차를 가하고 있습니다. 오메가 3 계열 약물은 스타틴 계열 약물이나 다른 지질저하제와 병용할 수 있기 때문에 복잡한 이상지질혈증 환자 관리에서 그 가치가 높아지고 있습니다. 또한, 오메가 3 처방 제제는 류마티스 관절염, 만성 신장 질환, 인지 기능 저하 등 심장 건강 이외의 증상에도 효과가 입증되어 그 치료 범위가 더욱 넓어지고 있습니다. 전 세계적으로 고령화와 만성질환의 부담이 증가하는 가운데, 오메가 3 처방약은 단순한 건강기능식품이 아닌 항염증 및 심장 보호 메커니즘을 가진 근거가 있는 의약품으로 인식되고 있습니다.

규제 당국의 승인과 임상시험은 어떻게 치료 용도를 확장하고 있는가?

규제 당국의 발전과 탄탄한 임상 연구는 오메가 3 처방약의 시장 가능성을 크게 넓히고 있습니다. FDA가 중증 고중성지방혈증에 대해 이코사펜토에틸, 오메가 3 산 에틸 에스테르 등 여러 오메가 3 제제를 승인한 것은 그 치료 효과를 검증하고 더 폭넓은 임상 적용의 길을 열어주었습니다. 한편, 현재 진행 중인 임상시험에서는 오메가 3의 알려진 항염증 및 세포막 안정화 효과에 힘입어 알츠하이머병, 양극성 장애, 건선, 특정 암 등의 치료에 오메가 3의 잠재적 활용 가능성을 검토하고 있습니다. EU와 아시아태평양에서는 규제 당국도 이러한 추세에 발맞춰 고순도 EPA, DHA 제제의 승인 및 급여 확대를 허용하고 있습니다. 제약사들은 특히 스타틴 불내성 환자나 심혈관계 위험이 남아있는 환자를 대상으로 오메가 3 약물의 병용요법 및 보조적 사용을 평가하기 위한 장기 임상시험에 대한 투자를 늘리고 있습니다. 생체 이용률을 높이고 위장 부작용을 최소화하기 위해 서방형 기술, 새로운 지질 캡슐화 시스템 등의 지적재산권 전략을 추구하고 있습니다. 이러한 개발은 오메가 3 처방약의 치료 영역을 확대할 뿐만 아니라, 혼잡한 심혈관계 치료 영역에서 경쟁사와의 차별화를 창출할 수 있을 것으로 기대됩니다. 규제 당국이 보다 타겟화된 맞춤형 치료 옵션을 요구하고 있는 가운데, 오메가 3 의약품은 생명을 위협하는 질환의 1차 예방과 2차 예방이라는 이중적인 역할을 수행한다는 점에서 지속적으로 지지를 받고 있습니다.

자연적이고 안전한 치료법에 대한 환자들의 요구가 오메가 3 의약품의 상황을 재구성하고 있는가?

자연스럽고 내약성이 좋으며 과학적으로 입증된 치료법에 대한 환자들의 관심이 높아지면서 오메가 3 처방약 시장을 재편하는 중요한 동력이 되고 있습니다. 많은 소비자들이 합성 약물의 장기적인 부작용에 대한 경각심을 갖게 되면서, 특히 만성질환 관리에서 오메가 3 요법은 우수한 안전성 프로파일과 천연 유래의 장점으로 인해 많은 소비자들에게 받아들여지고 있습니다. 이러한 경향은 특히 고령자나 여러 합병증을 앓고 있는 환자들 사이에서 더욱 강하게 나타나고 있으며, 장기적인 약리학적 관리가 필요하고, 보다 순하고 무해한 치료 옵션을 선호하는 경우가 많습니다. 시중에서 판매되는 어유 보충제와 달리, 처방전 오메가 3 의약품은 표준화된 용량, 관리된 순도, 임상적으로 검증된 결과를 제공함으로써 환자와 의사의 신뢰를 높이고 있습니다. 건강 관련 지식이 향상되고 환자가 치료 결정에 참여하면서 심장, 뇌, 관절 건강에서 오메가 3의 역할에 대한 인식이 높아져 시장 관련성이 더욱 강화되고 있습니다. 또한, 예방적 건강관리로의 전환은 오메가 3 처방약을 심혈관 위험을 관리하기 위한 예방적이고 생활습관적인 도구로 자리매김하고 있습니다. 원격의료 플랫폼과 전자 약국 서비스도 더 쉬운 접근, 더 광범위한 아웃리치, 더 나은 복약 순응도에 기여하고 있습니다. 제약사들은 소비자 캠페인, 디지털 교육, 개인화된 참여 전략 등을 통해 이러한 환자 인식의 증가를 활용하고 있습니다. '자연과 의약품의 융합'이라는 인식이 확산되고 있는 가운데, 오메가 3 의약품은 기존 약물요법과 웰니스 중심의 환자 우선 의료의 간극을 메우고 있습니다.

오메가 3 처방약 시장의 세계 성장 가속화의 원동력은?

오메가 3 처방약 시장의 성장은 임상 혁신, 만성질환의 유행, 규제 모멘텀, 의료 선호도 변화 등 여러 가지 요인에 의해 주도되고 있습니다. 주요 성장 요인 중 하나는 전 세계적으로 고지혈증, 당뇨병, 비만 등 심혈관계 질환 및 대사성 질환의 증가로 스타틴 계열 약물을 넘어선 지질 저하 보조요법에 대한 수요가 증가하고 있다는 점입니다. 또한, REDUCE-IT, JELIS와 같은 획기적인 임상시험에서 좋은 결과를 얻으면서 EPA에 초점을 맞춘 치료법의 임상적 입지가 강화되어 순환기내과 및 내과에서 채택이 확대되고 있습니다. 특히 북미, 유럽, 일본에서는 노인 인구가 증가하고 있으며, 고령화에 따른 CVD, 인지기능 저하, 염증 관련 질환의 증가가 수요를 더욱 증가시키고 있습니다. 상업적 측면에서는 제형 기술 및 용량 최적화에 대한 의약품의 혁신으로 약물의 내약성, 생체 이용률, 순응도가 향상되어 치료 결과를 개선하고 있습니다. 또한, 신흥 시장에서의 규제 당국의 승인 증가, 보험 적용률 증가, 공중 보건 캠페인도 시장 침투를 촉진하고 있습니다. 건강기능식품과 의약품의 경계가 모호해지면서 의약품과 건강기능식품의 제휴 및 하이브리드 비즈니스 모델의 문이 열리고 있습니다. 또한, 눈과 뇌 건강에서 관절의 움직임에 이르기까지 오메가 3의 광범위한 효능에 대한 인식이 높아지면서 의사들이 전인적 치료 계획에 오메가 3를 고려하고 있습니다. 이러한 움직임을 종합하면, 오메가 3 처방약은 틈새 시장인 순환기 보조제에서 전 세계 헬스케어 시스템 전반에서 주류가 될 수 있는 다기능 치료 솔루션으로 발전하고 있는 것으로 보입니다.

부문

의약품(바세파 의약품, 로바자 의약품, 기타 의약품), 유통 채널(소매 약국, 병원 약국, 온라인 약국), 용도(순환기 용도, 기타 용도)

조사 대상 기업 사례

  • Abbott Laboratories
  • Amarin Corporation plc
  • Apotex Inc.
  • AstraZeneca plc
  • BASF SE
  • Bayer AG
  • Camber Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc(GSK)
  • Grupo Ferrer Internacional, S.A.
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • Natrapharm, Inc.(Patriot Pharmaceutical Corp.)
  • Novartis International AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.08

Global Omega 3 Prescription Drugs Market to Reach US$1.6 Billion by 2030

The global market for Omega 3 Prescription Drugs estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Vascepa Drugs, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$821.2 Million by the end of the analysis period. Growth in the Lovaza Drugs segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$356.8 Million While China is Forecast to Grow at 5.5% CAGR

The Omega 3 Prescription Drugs market in the U.S. is estimated at US$356.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$302.9 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Omega-3 Prescription Drugs Market - Key Trends & Drivers Summarized

Why Are Omega-3 Prescription Drugs Gaining Clinical Ground in Cardiovascular and Metabolic Therapy?

Omega-3 prescription drugs are emerging as a crucial component in the pharmaceutical landscape, particularly for managing hypertriglyceridemia, cardiovascular disease (CVD), and other inflammation-driven chronic conditions. Unlike dietary supplements, these drugs are purified, concentrated, and clinically tested for efficacy and safety, offering higher dosages of eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) suitable for medical intervention. Their role in reducing triglyceride levels, improving lipid profiles, and mitigating residual cardiovascular risk has been validated in large-scale clinical trials such as REDUCE-IT, which demonstrated cardiovascular outcome benefits from high-dose icosapent ethyl (EPA). These findings have driven inclusion of omega-3-based therapies in various treatment guidelines and have spurred a surge in prescriptions by cardiologists and primary care providers alike. The ability of these drugs to function alongside statins and other lipid-lowering agents enhances their value in managing complex dyslipidemia cases. Additionally, omega-3 prescription formulations have proven beneficial in conditions beyond heart health, including rheumatoid arthritis, chronic kidney disease, and cognitive decline, further expanding their therapeutic scope. With an aging population and a rising burden of chronic diseases worldwide, omega-3 prescription drugs are increasingly viewed not just as supplements, but as evidence-backed pharmaceuticals with a unique anti-inflammatory and cardioprotective mechanism of action.

How Are Regulatory Approvals and Clinical Trials Expanding Therapeutic Applications?

Regulatory advancements and robust clinical research are significantly expanding the market potential for omega-3 prescription drugs. The FDA’s approval of multiple omega-3-based formulations-such as icosapent ethyl and omega-3 acid ethyl esters-for severe hypertriglyceridemia has validated their therapeutic efficacy, opening pathways for broader clinical adoption. Meanwhile, ongoing trials are investigating their potential use in treating conditions like Alzheimer’s disease, bipolar disorder, psoriasis, and certain cancers, fueled by omega-3s' known anti-inflammatory and cell membrane-stabilizing effects. In the EU and Asia-Pacific, regulatory agencies are also aligning with this trend, granting approvals and expanding reimbursement for high-purity EPA and DHA formulations. Pharmaceutical companies are increasingly investing in long-term studies to evaluate combination therapies and adjunctive uses of omega-3 drugs, particularly in statin-intolerant patients or those with persistent residual cardiovascular risk. Intellectual property strategies, such as extended-release technologies and novel lipid encapsulation systems, are being pursued to enhance bioavailability and minimize gastrointestinal side effects. These developments not only expand the therapeutic footprint of omega-3 prescription drugs but also create competitive differentiation in an otherwise crowded cardiovascular treatment space. As regulatory bodies demand more targeted and personalized treatment options, omega-3 drugs continue to gain traction for their dual role in both primary and secondary prevention of life-threatening conditions.

Is Patient Demand for Natural and Safe Therapies Reshaping the Omega-3 Pharmaceutical Landscape?

Rising patient interest in natural, well-tolerated, and science-backed therapies is a significant force reshaping the omega-3 prescription drug market. As more consumers grow wary of long-term side effects from synthetic drugs-especially in managing chronic conditions-omega-3 therapies are being embraced for their favorable safety profiles and natural origins. This trend is particularly strong among older adults and patients with multiple comorbidities, who often require long-term pharmacological management and prefer gentler, non-toxic treatment options. Unlike over-the-counter fish oil supplements, prescription omega-3 drugs offer standardized dosages, controlled purity, and clinically validated outcomes, all of which increase patient and physician trust. The rise in health literacy and patient involvement in treatment decisions has created greater awareness of omega-3s' role in heart, brain, and joint health, further reinforcing their market relevance. Additionally, the shift toward preventive healthcare is positioning omega-3 prescription drugs as proactive, lifestyle-aligned tools for managing cardiovascular risk. Telemedicine platforms and e-pharmacy services are also contributing to easier access, broader outreach, and better medication adherence. Pharmaceutical companies are leveraging this growing patient awareness through direct-to-consumer campaigns, digital education, and personalized engagement strategies. As the perception of "natural meets pharmaceutical-grade" continues to gain traction, omega-3 drugs are bridging the gap between traditional pharmacotherapy and wellness-centric, patient-preferred medicine.

What’s Fueling the Accelerated Growth of the Omega-3 Prescription Drugs Market Globally?

The growth in the omega-3 prescription drugs market is driven by several factors rooted in clinical innovation, chronic disease prevalence, regulatory momentum, and shifting healthcare preferences. One of the primary growth drivers is the global rise in cardiovascular and metabolic disorders-such as hyperlipidemia, diabetes, and obesity-which increase demand for adjunctive lipid-lowering therapies that go beyond statins. Additionally, favorable results from landmark studies like REDUCE-IT and JELIS have strengthened the clinical positioning of EPA-focused therapies, prompting widespread adoption in cardiology and internal medicine. The expanding elderly population-especially in North America, Europe, and Japan-is further contributing to demand, given the age-related increase in CVD, cognitive decline, and inflammation-related disorders. On the commercial side, pharmaceutical innovation in formulation technologies and dosage optimization has enhanced drug tolerability, bioavailability, and compliance, leading to improved therapeutic outcomes. Increasing regulatory approvals in emerging markets, coupled with rising insurance coverage and public health campaigns, are also facilitating market penetration. The blurring lines between nutraceuticals and pharmaceuticals have opened doors for pharma-nutrition collaborations and hybrid business models. Moreover, growing awareness of omega-3’s broader benefits-ranging from eye and brain health to joint mobility-is prompting physicians to consider it for holistic treatment plans. Collectively, these dynamics are pushing omega-3 prescription drugs from a niche cardiovascular add-on to a mainstream, multifunctional therapeutic solution across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Omega 3 Prescription Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Vascepa Drugs, Lovaza Drugs, Other Drugs); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies); Application (Cardiovascular Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • Amarin Corporation plc
  • Apotex Inc.
  • AstraZeneca plc
  • BASF SE
  • Bayer AG
  • Camber Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc (GSK)
  • Grupo Ferrer Internacional, S.A.
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
  • Novartis International AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Omega 3 Prescription Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Landmark Cardiovascular Outcomes Trials Spur Growth and Reinforce Clinical Credibility of Omega-3 Prescription Therapies
    • Rising Prevalence of Hypertriglyceridemia and Cardiometabolic Disorders Throws the Spotlight on High-Purity EPA Formulations
    • Here's How Shifting Physician and Payer Preferences Are Driving Adoption of Prescription-Grade Omega-3 Over OTC Supplements
    • Expanding Use in Adjunctive Therapy for Statin-Resistant and High-Risk Cardiovascular Patients Strengthens the Business Case
    • Advancements in Drug Delivery Systems Enhance Bioavailability and Minimize Gastrointestinal Side Effects
    • Growing Geriatric Population with Complex Comorbidities Accelerates Demand for Safe, Long-Term Lipid-Lowering Agents
    • Integration of Omega-3 Therapies in Precision Medicine Initiatives Expands Addressable Patient Populations
    • Here's the Story Behind How Preventive Healthcare Trends Are Driving Prescription Demand in Primary Care Settings
    • Increasing Pharmaceutical Investment in Omega-3 Pipeline Products Spurs Innovation in Formulation and Indication Scope
    • Global Shift Toward Value-Based Care and Outcomes-Driven Prescribing Supports Growth of Efficacious, Low-Risk Omega-3 Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Omega 3 Prescription Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Omega 3 Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Vascepa Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Vascepa Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Vascepa Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lovaza Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Lovaza Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Lovaza Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Omega 3 Prescription Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Omega 3 Prescription Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Omega 3 Prescription Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Omega 3 Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Omega 3 Prescription Drugs by Drug - Vascepa Drugs, Lovaza Drugs and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Omega 3 Prescription Drugs by Drug - Percentage Breakdown of Value Sales for Vascepa Drugs, Lovaza Drugs and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Omega 3 Prescription Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Omega 3 Prescription Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Omega 3 Prescription Drugs by Application - Cardiovascular Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Omega 3 Prescription Drugs by Application - Percentage Breakdown of Value Sales for Cardiovascular Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제